Introduction to gene therapy: a clinical aftermath

Methods Mol Biol. 2011:737:27-44. doi: 10.1007/978-1-61779-095-9_2.

Abstract

Despite three decades of huge progress in molecular genetics, in cloning of disease causative gene as well as technology breakthroughs in viral biotechnology, out of thousands of gene therapy clinical trials that have been initiated, only very few are now reaching regulatory approval. We shall review some of the major hurdles, and based on the current either positive or negative examples, we try to initiate drawing a learning curve from experience and possibly identify the major drivers for future successful achievement of human gene therapy trials.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic*
  • Cystic Fibrosis / genetics
  • Cystic Fibrosis / therapy
  • Genetic Therapy / legislation & jurisprudence
  • Genetic Therapy / methods*
  • Genetic Therapy / trends
  • Genetic Vectors / therapeutic use
  • Humans
  • Lipoprotein Lipase / genetics
  • Lipoprotein Lipase / therapeutic use
  • Muscular Dystrophy, Duchenne / genetics
  • Muscular Dystrophy, Duchenne / therapy
  • Parkinson Disease / genetics
  • Parkinson Disease / therapy
  • Peripheral Vascular Diseases / genetics
  • Peripheral Vascular Diseases / therapy
  • Severe Combined Immunodeficiency / therapy

Substances

  • Lipoprotein Lipase